RxSight (RXST) Capital Expenditures Growth (1y) (2021 - 2026)
RxSight (RXST) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | -1.00% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 10.38% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 24.20% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 35.70% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -9.99% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 16.28% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -4.32% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | -6.52% |
| 10 | RxSight | 248.32 Mn | -155.92 Mn | - | 27.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.26% |
| Mar 31, 2026 | 272.06% |
| Dec 31, 2025 | -66.23% |
| Sep 30, 2025 | -279.24% |
| Jun 30, 2025 | 25.28% |
| Mar 31, 2025 | -89.63% |
| Dec 31, 2024 | -46.76% |
| Sep 30, 2024 | -60.82% |
| Jun 30, 2024 | 922.15% |
| Mar 31, 2024 | 659.46% |
| Dec 31, 2023 | 191.86% |
| Sep 30, 2023 | 385.34% |
| Jun 30, 2023 | -86.22% |
| Mar 31, 2023 | -30.00% |
| Dec 31, 2022 | -1,155.07% |
| Sep 30, 2022 | 149.03% |
| Jun 30, 2022 | 31.35% |
| Mar 31, 2022 | -25.70% |
| Dec 31, 2021 | 92.96% |
| Sep 30, 2021 | -296.19% |